"Infusions, Intravenous" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
The long-term (minutes to hours) administration of a fluid into the vein through venipuncture, either by letting the fluid flow by gravity or by pumping it.
| Descriptor ID |
D007262
|
| MeSH Number(s) |
E02.319.267.082.500 E02.319.267.510.590
|
| Concept/Terms |
Intravenous Drip- Intravenous Drip
- Drip, Intravenous
- Drip Infusions
- Drip Infusion
- Infusion, Drip
- Infusions, Drip
|
Below are MeSH descriptors whose meaning is more general than "Infusions, Intravenous".
Below are MeSH descriptors whose meaning is more specific than "Infusions, Intravenous".
This graph shows the total number of publications written about "Infusions, Intravenous" by people in this website by year, and whether "Infusions, Intravenous" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1994 | 0 | 3 | 3 |
| 1995 | 0 | 1 | 1 |
| 1996 | 0 | 1 | 1 |
| 1997 | 0 | 4 | 4 |
| 1998 | 0 | 1 | 1 |
| 1999 | 0 | 1 | 1 |
| 2000 | 0 | 2 | 2 |
| 2001 | 0 | 1 | 1 |
| 2002 | 0 | 1 | 1 |
| 2003 | 0 | 3 | 3 |
| 2005 | 1 | 2 | 3 |
| 2006 | 0 | 8 | 8 |
| 2007 | 0 | 3 | 3 |
| 2008 | 0 | 2 | 2 |
| 2009 | 0 | 3 | 3 |
| 2010 | 0 | 3 | 3 |
| 2011 | 0 | 8 | 8 |
| 2012 | 0 | 4 | 4 |
| 2013 | 0 | 1 | 1 |
| 2014 | 0 | 4 | 4 |
| 2015 | 0 | 1 | 1 |
| 2016 | 0 | 2 | 2 |
| 2017 | 0 | 3 | 3 |
| 2018 | 0 | 2 | 2 |
| 2019 | 0 | 3 | 3 |
| 2020 | 0 | 4 | 4 |
| 2021 | 0 | 2 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Infusions, Intravenous" by people in Profiles.
-
Abelacimab for Prevention of Venous Thromboembolism. N Engl J Med. 2021 08 12; 385(7):609-617.
-
CPX-351 versus 7+3 cytarabine and daunorubicin chemotherapy in older adults with newly diagnosed high-risk or secondary acute myeloid leukaemia: 5-year results of a randomised, open-label, multicentre, phase 3 trial. Lancet Haematol. 2021 Jul; 8(7):e481-e491.
-
Criteria for Emergency Brain MRI During Stroke-Alert. J Stroke Cerebrovasc Dis. 2021 Aug; 30(8):105890.
-
Low-dose prostaglandin E1 is safe and effective for critical congenital heart disease: is it time to revisit the dosing guidelines? Cardiol Young. 2021 Jan; 31(1):63-70.
-
The ligament of Marshall and arrhythmias: A review. Pacing Clin Electrophysiol. 2021 May; 44(5):792-799.
-
Safety results of administering ocrelizumab per a shorter infusion protocol in patients with primary progressive and relapsing multiple sclerosis. Mult Scler Relat Disord. 2020 Nov; 46:102454.
-
Shared decision making, thrombotic thrombocytopenic purpura, and caplacizumab. Am J Hematol. 2020 04; 95(4):E76-E77.
-
Vancomycin dosing in critically ill trauma patients: The VANCTIC Study. J Trauma Acute Care Surg. 2019 11; 87(5):1164-1171.
-
Randomized phase 2 trial comparing JNJ-9375, a thrombin-directed antibody, with apixaban for prevention of venous thrombosis. J Thromb Haemost. 2019 12; 17(12):2081-2088.
-
Randomized Trial of Intravenous Versus Intraperitoneal Chemotherapy Plus Bevacizumab in Advanced Ovarian Carcinoma: An NRG Oncology/Gynecologic Oncology Group Study. J Clin Oncol. 2019 06 01; 37(16):1380-1390.